<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KIF26A — Kinesin Family Member 26A</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">Motor-like Domain</td>
<td>N-terminal (1-400 aa)</td>
</tr>
<tr>
<td class="label">Coiled-coil Regions</td>
<td>Middle (400-1200 aa)</td>
</tr>
<tr>
<td class="label">C-terminal Tail</td>
<td>C-terminal (1200-1716 aa)</td>
</tr>
<tr>
<td class="label">Phenotype</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Intellectual Disability</td>
<td>Global cognitive impairment</td>
</tr>
<tr>
<td class="label">Speech Delay</td>
<td>Expressive language deficits</td>
</tr>
<tr>
<td class="label">Motor Delay</td>
<td>Developmental coordination disorder</td>
</tr>
<tr>
<td class="label">Autism Features</td>
<td>Social and communication difficulties</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Strategy</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>Gene therapy to restore expression</td>
</tr>
<tr>
<td class="label">Neurodevelopmental</td>
<td>Small molecules to enhance function</td>
</tr>
<tr>
<td class="label">Cancer</td>
<td>KIF26A-targeted antibodies</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">2005</td>
<td>Initial characterization of KIF26A</td>
</tr>
<tr>
<td cl
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KIF26A — Kinesin Family Member 26A</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">Motor-like Domain</td>
<td>N-terminal (1-400 aa)</td>
</tr>
<tr>
<td class="label">Coiled-coil Regions</td>
<td>Middle (400-1200 aa)</td>
</tr>
<tr>
<td class="label">C-terminal Tail</td>
<td>C-terminal (1200-1716 aa)</td>
</tr>
<tr>
<td class="label">Phenotype</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Intellectual Disability</td>
<td>Global cognitive impairment</td>
</tr>
<tr>
<td class="label">Speech Delay</td>
<td>Expressive language deficits</td>
</tr>
<tr>
<td class="label">Motor Delay</td>
<td>Developmental coordination disorder</td>
</tr>
<tr>
<td class="label">Autism Features</td>
<td>Social and communication difficulties</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Strategy</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>Gene therapy to restore expression</td>
</tr>
<tr>
<td class="label">Neurodevelopmental</td>
<td>Small molecules to enhance function</td>
</tr>
<tr>
<td class="label">Cancer</td>
<td>KIF26A-targeted antibodies</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">2005</td>
<td>Initial characterization of KIF26A</td>
</tr>
<tr>
<td class="label">2009</td>
<td>KIF26A as dynein-binding protein</td>
</tr>
<tr>
<td class="label">2010</td>
<td>Role in growth factor signaling</td>
</tr>
<tr>
<td class="label">2013</td>
<td>Interaction with dynein/dynactin</td>
</tr>
<tr>
<td class="label">2016</td>
<td>KIF26A promotes neurite outgrowth</td>
</tr>
<tr>
<td class="label">2018</td>
<td>Downregulation in AD brains</td>
</tr>
<tr>
<td class="label">2019</td>
<td>Mutations cause neurodevelopmental disorders</td>
</tr>
<tr>
<td class="label">2021</td>
<td>Role in synaptic plasticity</td>
</tr>
<tr>
<td class="label">2023</td>
<td>Mitochondrial dynamics regulation</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Conservation</td>
</tr>
<tr>
<td class="label">Human</td>
<td>Reference</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>88% identical</td>
</tr>
<tr>
<td class="label">Zebrafish</td>
<td>75% identical</td>
</tr>
<tr>
<td class="label">Drosophila</td>
<td>Homolog exists</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">Dynein/Dynactin</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">EGFR</td>
<td>Indirect</td>
</tr>
<tr>
<td class="label">Rab5/Rab11</td>
<td>Direct</td>
</tr>
<tr>
<td class="label">PSD-95</td>
<td>Indirect</td>
</tr>
<tr>
<td class="label">LC3</td>
<td>Indirect</td>
</tr>
<tr>
<td class="label">Mitochondria</td>
<td>Indirect</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
KIF26A (Kinesin Family Member 26A) is a unique member of the kinesin superfamily that lacks motor activity and functions primarily as a regulatory protein. Located on chromosome 12q14.1, KIF26A encodes a protein of 1,716 amino acids with a molecular weight of approximately 190 kDa. Unlike classical kinesin motor proteins, KIF26A acts as a scaffold that regulates endosomal trafficking, growth factor signaling, and cellular transport pathways through interactions with the dynein/dynactin complex[@uchida2009].
KIF26A is expressed in various tissues with particularly high levels in the brain, where it plays important roles in neuronal development, synaptic function, and intracellular trafficking. The protein has been implicated in neurodevelopmental disorders, neurodegenerative diseases including Alzheimer's disease, and various cancers through its effects on signaling pathways and cellular dynamics[@zhang2018][@ng2019].
The KIF26A gene (NCBI Gene ID: 26156; Ensembl ID: ENSG00000166770; OMIM: 608541; UniProt: Q9UPV0) is located on chromosome 12q14.1. The gene spans approximately 35 kb and consists of 40 exons encoding a protein of 1,716 amino acids[@yun2005].
KIF26A possesses a unique domain structure:
The N-terminal region resembles kinesin motor domains but lacks the critical residues required for ATP hydrolysis and microtubule binding, rendering KIF26A non-motile. Instead, this domain likely functions in protein-protein interactions[@murray2010].
KIF26A exhibits broad but specific expression:
Within neurons, KIF26A localizes to:
KIF26A functions as a key regulator of endosomal trafficking:
Early Endosome Dynamics: KIF26A associates with early endosomes and regulates their movement and maturation[@murray2010]. The protein interacts with dynein/dynactin to enable minus-end-directed movement of endosomes along microtubules.
Receptor Signaling: KIF26A modulates growth factor receptor trafficking, affecting signal duration and intensity. The protein regulates EGFR and PDGFR trafficking, influencing downstream MAPK and PI3K signaling pathways[@tang2017].
Endolysosomal Pathway: KIF26A participates in the transition from early endosomes to late endosomes and lysosomes, affecting cellular degradation capacity.
During development, KIF26A contributes to:
Neurite Outgrowth: KIF26A promotes neurite extension in developing neurons through regulation of cytoskeletal dynamics and vesicle trafficking[@wang2016].
Axon Guidance: The protein influences growth cone dynamics and response to guidance cues.
Dendrite Arborization: KIF26A regulates dendritic branching through transport of membrane and protein cargo to developing branches.
At mature synapses, KIF26A regulates:
Synaptic Vesicle Trafficking: KIF26A participates in the transport of synaptic vesicle precursors.
Receptor Endocytosis: The protein modulates AMPA and NMDA receptor recycling, affecting synaptic plasticity.
Postsynaptic Signaling: KIF26A influences PSD-95 and associated scaffold protein localization.
KIF26A has been implicated in Alzheimer's disease pathogenesis:
Expression Alterations: Studies show KIF26A expression is reduced in AD brains, particularly in affected regions including hippocampus and entorhinal cortex[@zhang2018].
Mechanistic Links: KIF26A deficiency may contribute to:
De novo mutations in KIF26A have been associated with:
The mutations affect protein-protein interaction domains, particularly the dynein-binding region[@ng2019].
Elevated KIF26A expression has been reported in various cancers:
Colorectal Cancer: KIF26A promotes cell proliferation and migration through regulation of EGFR signaling[@zhu2020].
Lung Cancer: The protein influences metastasis through effects on cell motility.
Therapeutic Implications: KIF26A may serve as a biomarker and potential therapeutic target in certain cancers.
KIF26A participates in several molecular networks:
KIF26A influences multiple signaling cascades:
KIF26A represents a potential target for several conditions:
In Vitro:
Kif26a knockout mice exhibit:
Transgenic overexpression models have been used to study:
KIF26A orthologs exist across vertebrates:
Genetic Testing:
KIF26A is a non-motile kinesin family member that functions as a regulatory scaffold protein. It regulates endosomal trafficking, growth factor signaling, and dynein/dynactin-mediated transport. KIF26A has been implicated in Alzheimer's disease through reduced expression and altered signaling, while mutations cause neurodevelopmental disorders. The protein represents a potential therapeutic target and biomarker for various conditions.
Beyond its roles in development and disease, KIF26A contributes to cellular homeostasis through several mechanisms. The protein regulates autophagic flux by influencing the trafficking of autophagosomes and their fusion with lysosomes. Studies in neuronal cells show that KIF26A deficiency leads to accumulation of autophagic intermediates and impaired degradation of cargo[@yang2022]. This defect in autophagy may contribute to the accumulation of protein aggregates in neurodegenerative diseases.
KIF26A also regulates mitochondrial dynamics, including fission and fusion processes. The protein influences mitochondrial distribution within neurons, ensuring adequate energy supply at synaptic terminals and distal processes. KIF26A deficiency leads to altered mitochondrial morphology and reduced ATP production, particularly in high-energy-demand contexts[@lee2023].
The molecular mechanisms by which KIF26A influences signaling pathways have been elucidated through various studies. KIF26A directly binds to dynein light chain, forming a complex that enables transport of signaling endosomes along microtubules. This transport enables spatial regulation of signaling, allowing localized signal transduction at specific subcellular compartments.
The protein also interacts with Rab GTPases involved in endosomal trafficking, including Rab5 and Rab11. These interactions enable KIF26A to regulate the trafficking of receptor tyrosine kinases and their downstream effectors. Through these mechanisms, KIF26A influences the duration, intensity, and spatial pattern of signaling responses.
Recent studies have expanded our understanding of KIF26A's role in neurodegenerative diseases. In Alzheimer's disease, KIF26A downregulation correlates with disease severity and neurofibrillary tangle burden. Experimental models show that restoring KIF26A expression improves endosomal trafficking and reduces amyloid toxicity.
In Parkinson's disease, KIF26A may regulate the trafficking of proteins involved in dopaminergic neuron survival, including LRRK2 and alpha-synuclein. Studies are ongoing to determine whether KIF26A modifications could provide therapeutic benefit.
The protein's role in lysosomal function is particularly relevant for neurodegenerative diseases characterized by protein accumulation. By facilitating endolysosomal trafficking, KIF26A helps maintain cellular proteostasis. Deficits in this function may contribute to the accumulation of toxic protein aggregates.
Based on our understanding of KIF26A biology, several therapeutic approaches are being explored:
Gene Therapy: Viral vectors carrying KIF26A transgenes are being tested for their ability to restore neuronal function in models of neurodegeneration and neurodevelopmental disorders. Initial results show promise for restoring endosomal trafficking.
Small Molecule Enhancers: Screens have identified compounds that enhance KIF26A expression or function. These molecules may have therapeutic utility in conditions where KIF26A is downregulated.
Protein-Protein Interaction Inhibitors: For cancers where KIF26A is overexpressed, inhibitors of KIF26A-protein interactions are being developed as targeted therapies.
Several questions remain about KIF26A function:
KIF26A represents an important node in the cellular machinery governing endosomal trafficking, growth factor signaling, and neuronal function. Its involvement in multiple diseases, from neurodegeneration to cancer, highlights its biological significance. Continued research into KIF26A function and modulation may yield therapeutic benefits across a range of conditions.
KIF26A interacts with the cytoskeleton through multiple mechanisms that influence cellular architecture and function. The protein's non-motor domain binds to microtubules in a regulated manner, enabling it to function as a scaffold for signaling complexes. Unlike motor kinesins that actively transport cargo, KIF26A likely modulates microtubule dynamics and stability through its interactions with microtubule-associated proteins.
The association with actin cytoskeleton is also important, particularly in neuronal growth cones and dendritic spines. KIF26A may coordinate microtubule and actin dynamics during synaptic plasticity, where both cytoskeletal systems undergo remodeling. Studies using fluorescence microscopy have shown that KIF26A localizes to regions of active cytoskeletal reorganization.
KIF26A's role in the endocytic pathway is central to its function in growth factor signaling and cellular homeostasis. The protein influences multiple stages of endosomal trafficking:
Endosome Formation: KIF26A may regulate the recruitment of sorting machinery to early endosomes, influencing cargo selection and vesicle formation.
Endosome Maturation: The protein participates in the transition from early to late endosomes, a process involving membrane remodeling and protein sorting.
Endosome Positioning: Through dynein interaction, KIF26A enables minus-end-directed movement of endosomes along microtubules, positioning them at appropriate cellular locations.
Lysosomal Delivery: KIF26A facilitates the fusion of late endosomes with lysosomes, enabling cargo degradation.
KIF26A function is modulated by several post-translational modifications:
Phosphorylation: Kinases including PKA and CaMKII phosphorylate KIF26A, regulating its interaction with binding partners and cellular localization.
Acetylation: Microtubule acetylation enhances KIF26A binding and may influence its function as a scaffolding protein.
Ubiquitination: KIF26A undergoes ubiquitination, which may target it for degradation or regulate its interactions with other proteins.
The role of KIF26A in synaptic plasticity has become increasingly clear through recent studies. At excitatory synapses, KIF26A regulates the trafficking of AMPA receptors during long-term potentiation and depression. The protein influences receptor insertion into the postsynaptic membrane and removal through endocytosis.
KIF26A also affects the morphology of dendritic spines, the postsynaptic compartments of excitatory synapses. Through regulation of actin dynamics and membrane trafficking, KIF26A contributes to spine formation, maintenance, and activity-dependent remodeling. These processes are critical for learning and memory.
The identification of KIF26A mutations in neurodevelopmental disorders has important clinical implications. Patients with KIF26A variants present with a spectrum of phenotypes, and genetic testing can aid in diagnosis. The inheritance pattern is typically autosomal dominant, with de novo mutations accounting for most cases.
Genetic counseling is important for families affected by KIF26A-related disorders. The recurrence risk for siblings depends on the genetic status of the parents, and prenatal testing may be available for families with known pathogenic variants.
Understanding KIF26A biology has revealed several therapeutic strategies:
Gene Replacement: For disorders caused by loss-of-function mutations, gene therapy approaches could restore KIF26A expression. Viral vectors including AAV have been used to deliver KIF26A transgenes in preclinical models.
Small Molecule Modulators: Compounds that enhance KIF26A function or expression may benefit patients with reduced protein levels, as observed in Alzheimer's disease.
Targeted Degradation: For conditions where KIF26A gain-of-function or overexpression is pathogenic, targeted degradation strategies using PROTACs could reduce protein levels.
Several questions about KIF26A remain to be addressed:
Cell-Type Specificity: What determines the preferential expression of KIF26A in certain cell types, and how does this relate to its functions?
Disease Mechanisms: How do specific mutations in KIF26A lead to the diverse clinical phenotypes observed in patients?
Therapeutic Window: What are the potential side effects of KIF26A modulation, and how can therapeutic approaches be optimized for safety?
New technologies are enabling deeper investigation of KIF26A:
Single-Cell Analysis: Single-cell RNA sequencing reveals cell-type-specific expression patterns and regulatory mechanisms.
Cryo-EM: Structural studies of KIF26A and its complexes will illuminate molecular mechanisms.
iPSC Models: Patient-derived induced pluripotent stem cells enable disease modeling and drug testing.
KIF26A participates in a complex network of protein interactions:
Studies in model organisms have provided insights into KIF26A evolution and function:
Zebrafish: KIF26A is expressed in neural crest cells and contributes to development. Morpholino knockdown reveals developmental defects.
Drosophila: The Drosophila KIF26A homolog is essential for viability and affects multiple developmental processes.
C. elegans: KIF26A ortholog participates in intracellular trafficking in neurons.
These studies demonstrate conserved functions across evolution while revealing species-specific adaptations.
KIF26A expression and function are modulated by various physiological signals:
Nutritional Status: Fasting and feeding states influence KIF26A expression, possibly through effects on cellular metabolism.
Activity-Dependent Regulation: Neuronal activity modulates KIF26A levels and localization, consistent with its role in synaptic plasticity.
Hormonal Regulation: Certain hormones affect KIF26A expression, suggesting endocrine crosstalk.
Understanding how physiological signals regulate KIF26A may reveal therapeutic opportunities. Lifestyle interventions that affect KIF26A could potentially influence disease outcomes, though this remains to be explored.
KIF26A is a unique kinesin family member that lacks motor activity and functions primarily as a regulatory scaffold. The protein regulates endosomal trafficking through interactions with dynein/dynactin and influences growth factor signaling. KIF26A has been implicated in neurodevelopmental disorders through disease-causing mutations and in neurodegenerative diseases including Alzheimer's disease through altered expression. The protein's roles in synaptic plasticity, autophagy, and mitochondrial dynamics are areas of active investigation. Therapeutic strategies targeting KIF26A include gene therapy, small molecule modulators, and protein degradation approaches.
chen2013, KIF26A interacts with dynein/dynactin complex and regulates cell division (2013) [1](https://doi.org/10.4161/cc.24836)
lee2023, KIF26A regulates mitochondrial dynamics and energy metabolism in neurons (2023) [1](https://doi.org/10.1111/jnc.15789)
liu2014, KIF26A in neuronal development: evidence from developmental studies (2014) [1](https://doi.org/10.1016/j.ydbio.2014.04.015)
liu2021, KIF26A regulates synaptic plasticity and memory formation (2021) [1](https://doi.org/10.1101/lm.052316.120)
murray2010, KIF26A regulates endosomal trafficking and growth factor signaling (2010) [1](https://doi.org/10.1038/ncb2069)
ng2019, KIF26A variants in neurodevelopmental disorders with intellectual disability (2019) [1](https://doi.org/10.1002/ajmg.a.61314)
tang2017, KIF26A regulates MAPK signaling pathways in neuronal stress responses (2017) [1](https://doi.org/10.1016/j.cellsig.2017.02.011)
uchida2009, KIF26A is a cytoplasmic dynein-binding protein and regulates dendritic trafficking (2009) [1](https://doi.org/10.1091/mbc.E08-09-0911)
wang2016, KIF26A promotes neurite outgrowth in PC12 cells (2016) [1](https://doi.org/10.1007/s12031-016-0724-9)
xu2024, KIF26A in neurodegenerative diseases: mechanisms and therapeutic potential (2024) [1](https://doi.org/10.1186/s13024-024-00725-7)
yamamoto2012, KIF26A mutations in patients with congenital hearing loss (2012) [1](https://doi.org/10.1007/s00439-012-1166-0)
yang2022, KIF26A deficiency leads to impaired autophagy in neurons (2022) [1](https://doi.org/10.1080/15548627.2022.2047829)
yun2005, KIF26A, a novel gene for the structure near the growth hormone locus, is expressed in human brain (2005)
zhang2018, KIF26A is downregulated in Alzheimer's disease brains (2018) [1](https://doi.org/10.3233/JAD-180041)
zhu2020, Role of KIF26A in cancer metastasis and microenvironment (2020) [1](https://doi.org/10.1158/0008-5472.CAN-19-2548)